Previous 10 | Next 10 |
Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...
Deutsche Bank research has lowered its forecasts for EPS growth for contract research organizations (CROs) and has cut its price target on two stocks - Charles River Laboratories ( NYSE: CRL ) and ICON plc ( NASDAQ: ICLR ). "We stress tested our models for enduring m...
A growing chorus of economists has been predicting a recession in the U.S. this year or next. In such an environment, finding companies with economically resilient revenue and earnings streams may be hard to do -- but not impossible. In fact, contract research organization (CRO) stocks ...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2022 financial results on Wednesday, August 3 rd , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 3 rd , at 9:30 a.m. ET. In...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Charles River Laboratories (NYSE:CRL) has opened a 16K sq ft manufacturing facility in Cheshire, UK. The High Quality (HQ) Plasmid DNA Centre of Excellence is located at Bruntwood SciTech's Alderley Park in Cheshire and will enable the contract research organization to expand its end-to-end c...
Cheshire-based site to bolster plasmid DNA manufacturing, supporting cell and gene therapy development Charles River Laboratories International, Inc. (NYSE: CRL) announced today the opening of its High Quality (HQ) Plasmid DNA Centre of Excellence at Bruntwood SciTech’...
On June 9, Enzo Biochem announced a new strategic review that may finally lead to the sale of the long-mismanaged company. Since late 2021, positive changes have taken place - long-time CEO Rabbani was replaced with an independent CEO, an experienced activist was appointed to the Boar...
Charles River Laboratories International (NYSE:CRL) and Ziphius Vaccines signed an agreement to make starting materials for early-stage clinical supply of plasmid DNA for drug substance manufacturing. Ziphius Vaccines is developing a proprietary self-amplifying mRNA (saRNA) technology pl...
Program aimed to deliver early-stage clinical supply of plasmid DNA for drug substance manufacturing Charles River Laboratories International, Inc. (NYSE: CRL) and Ziphius Vaccines, a biopharmaceutical company developing self-amplifying RNA (saRNA) based medicinal products f...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...